Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuranolone in Post-stroke Depression
NCT06759558Phase 2Recruiting
- Sponsor
- Duke University
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of zuranolone in major depressive disorder (MDD), sponsored by Duke University. Started Jan 2026; status: recruiting.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06759558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759558.